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 Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer 
characterized by the lack of HER2, estrogen and progesterone receptors. Mutation to the 
BRCA1/2 gene increases susceptibility to several types of cancer, including breast and 
ovarian, and women with germline BRCA1 or BRCA2 mutations are estimated to have a 
lifetime risk of 50-85% of developing breast cancer.1 Frequency of BRCA mutation is 
observed to be higher in patients with TNBC (~20%) relative to all breast cancer subtypes 
(~5%).2 BRCA mutation is also correlated with a younger age at diagnosis and a higher risk 
of recurrence.3,7 By reviewing TNBC cases seen by Lehigh Valley Health Network (LVHN) in 
2013-14, we show that all treatments offered by LVHN are in accordance with the national 
standard and that 16% of patients tested were positive for BRCA1 mutation. 
Introduction 
 Female breast cancer is estimated to be the most common type of cancer diagnosed 
in 2015, representing 14% of all new cancer cases in the United States.4 Prognoses vary 
based on the expression of certain receptor proteins by the breast tumor: those expressing 
receptors to estrogen (ER) or progesterone (PR) can be treated with systemic endocrine 
chemotherapy in the form of tamoxifen or aromatase inhibitor, which are effective 
treatments with mild side effects.5 Breast cancers can also overexpress receptors to human 
epidermal growth factor (HER2)—these tumors exhibit rapid growth and sensitivity to 
treatment with a monoclonal antibody such as trastuzumab, which is also well tolerated.6 
Breast cancers expressing neither endocrine receptors nor HER2 are called triple-negative 
and are associated with a poor prognosis due to their resistance to the targeted hormonal 
or HER2 therapies as well as their apparent aggressiveness relative to other types of breast 
cancer.7 Triple-negative breast cancer (TNBC) has been observed to develop more 
frequently in pre-menopausal or younger women and displays both higher mitotic grade 
and larger tumor size at diagnosis.7 It is estimated that 15-20% of all breast cancers 
diagnosed in the United States are triple-negative.3  
Susceptibility to TNBC may arise from mutations to the genes BRCA1/2, which 
encode central proteins to many DNA repair and cell cycle regulatory macromolecular 
complexes.8 At least 13 different tumor suppressor proteins have been found to interact 
with BRCA1 and BRCA2 and function in homologous-recombination-mediated DNA repair, 
Review of Triple Negative Breast Cancer Cases Treated at 
Lehigh Valley Health Network in 2013-14 
apoptosis and cell cycle regulation.8 Women with BRCA mutations are estimated to have a 
lifetime risk of developing breast cancer of 50-85%.1 BRCA mutations are more common in 
patients with TNBC (~20%) relative to all breast cancer subtypes (~5%).2 In TNBC 
patients, BRCA mutations have also been correlated with a younger age at diagnosis.3,7 It is 
recommended that all patients diagnosed with TNBC receive genetic screening for BRCA 
mutation.9 
Breast cancer was the most common type of cancer treated at Lehigh Valley Health 
Network (LVHN) in 2013 and 2014. One goal of this study is to determine whether 
treatments offered to patients with TNBC at LVHN in 2013-14 were in agreement with the 
National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology for 
Breast Cancer, Version 2.2015. We also determine the frequency of BRCA mutation in the 
population of TNBC patients seen by LVHN who were referred to genetic counseling and 
were tested for BRCA mutation. We show that the treatment offered to TNBC patients by 
LVHN in 2013 and 2014 was in accordance with the NCCN Guidelines and that 16% of 
patients who received genetic testing were positive for a BRCA mutation. 
Methods 
 All charts of patients who were diagnosed and treated for TNBC at LVHN during 
2013 and 2014 were reviewed. 69 total charts were examined: it was found that 5 of these 
cases were not triple-negative, 1 had no follow-up, and 1 transferred care. The remaining 
62 charts were reviewed for information on the patient’s age, staging, and treatment, which 
was determined from all recorded transcriptions including pathology results. Genetic 
consultations and test results were also reviewed to determine the presence of BRCA 
mutation. All data analysis was performed using Microsoft Excel. Comparison to the NCCN 
Practice Guidelines in Oncology for Breast Cancer Version 2.2015 was made to determine 
whether the treatments offered by LVHN were in accordance with the national standard.  
Results 
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 The first goal of our study is to determine whether treatments offered to TNBC 
patients at LVHN in 2013-14 were in accordance with the NCCN guidelines. In total, 62 
cases of TNBC were reviewed [Table 1]. There were two patients with Stage 0 breast 
cancers: one was treated with lumpectomy and radiation, and the other was treated with 
mastectomy [Figure 1]. Both patients had regular follow up visits. These treatments are in 
accordance with the recommended NCCN guidelines for the treatment of ductal carcinoma 
in situ which state that either lumpectomy with adjuvant radiation or mastectomy followed 
by observation and yearly mammograms are appropriate treatments.10 
 There were 23 patients who presented with Stage I TNBC [Table 1]. All of these 
patients were also Stage IA meaning that their tumor was less than 2 cm in its greatest 
dimension without involvement of the lymph nodes.10 All 23 of the patients received 
surgery [Figure 1]. Of these, 16 received breast-conserving surgery, 15 received adjuvant 
radiation therapy and 1 declined radiation [Figure 1]. The remaining 7 received 
mastectomies, one of whom went on to receive adjuvant radiation due to her high risk of 
recurrence [Figure 1]. Of these 23 patients, 16 received adjuvant chemotherapy, 2 were 
offered chemotherapy but declined, 2 were ineligible for chemotherapy due to their 
comorbid conditions, and 3 were not recommended chemotherapy due to the size of their 
Figure 1. Treatments received by TNBC patients at Lehigh Valley Health Network in 2013-14. Surgery includes 
either lumpectomy or mastectomy, with surgical axillary staging. Chemotherapy for Stage I patients was given in 
the adjuvant setting, while chemotherapy for Stage II and III patients was given in either the neoadjuvant or 
adjuvant setting depending on the tumor size and the timing of the surgery: treatments include combined 
Adriamycin and Cytoxan followed by Taxol, combined Taxol and Cytoxan, or weekly Taxol. Chemotherapy for 
Stage IV patients includes the above drugs as well as Doxil, Ixempra, combined carboplatin and gemcitabine, 
epirubicin, vinorelbine, Xeloda, or 5-fluorouracil given palliatively. Radiation (XRT) includes brachytherapy or 
beam radiation given in either the adjuvant or palliative setting to the whole breast, axilla, or chest wall. Patients 
with comorbid conditions were ineligible for chemotherapy and/or radiation. 
tumor [Figure 1]. All 23 patients attended regular follow up visits. These treatments 
offered are in accordance with the recommended NCCN guidelines for treatment of 
localized invasive TNBC which state that either lumpectomy with adjuvant radiation or 
mastectomy are appropriate treatments, and which recommend chemotherapy in triple-
negative tumors greater than 1 cm in greatest dimension or consideration of chemotherapy 
in triple-negative tumors greater than 0.5 cm with no lymph node involvement.10 In 
addition, patients are recommended to attend follow up appointments regularly and 
receive yearly mammograms.10 
 There were 21 patients diagnosed with Stage II TNBC [Table 1]. Of these 21, 14 were 
Stage IIA, which is defined as any tumor between 2 and 5 cm in greatest dimension without 
metastasis to lymph nodes or any tumor less than 2 cm in greatest dimension with 
metastasis to movable ipsilateral axillary lymph nodes.10 The other 7 patients were 
diagnosed as Stage IIB, which is defined as any tumor greater than 5 cm in greatest 
dimension without lymph node metastasis or any tumor between 2 and 5 cm in greatest 
dimension with metastasis to movable ipsilateral axillary lymph nodes.10 All 21 of the Stage 
II patients received surgery: 13 patients received mastectomy and 8 received lumpectomy 
[Figure 1]. 15 of these patients received chemotherapy, either in the neoadjuvant or 
adjuvant setting, 2 declined chemotherapeutic treatment, and 3 were ineligible for 
chemotherapy due to comorbid conditions [Figure 1]. 13 patients received adjuvant 
radiation therapy, 5 declined radiation, and 2 were not recommended to receive radiation 
[Figure 1]. One patient had cerebral palsy and was recommended to receive neither 
chemotherapy nor radiation because she would not tolerate the treatments [Figure 1]. All 
21 patients did attend follow up visits. All of the treatments offered by LVHN for Stage II 
TNBC are in accordance with the recommended NCCN guidelines for treatment of localized 
invasive TNBC depending on the tumor size: neoadjuvant chemotherapy followed by 
breast-conserving surgery and adjuvant radiation may be given if the cancer responds 
sufficiently to the neoadjuvant treatment, with the option of mastectomy if the disease 
progresses during the neoadjuvant treatment.10 Total mastectomy without neoadjuvant 
chemotherapy remains an option as well.10 Adjuvant radiation is recommended for 
consideration in mastectomy patients who have axillary lymph node metastases, a tumor 
greater than 5 cm in greatest dimension, positive surgical margins or negative margins less 
than 1 mm.10 In addition, patients are recommended to attend follow up appointments 
regularly and receive yearly mammograms.10 
 There were 13 patients diagnosed with Stage III TNBC [Table 1]. Of these, 6 were 
Stage IIIA, which is defined as any sized tumor with metastases in ipsilateral axillary lymph 
nodes that are fixed to one another, or in ipsilateral internal mammary lymph nodes in the 
absence of axillary lymph node metastases.10 Tumors metastatic to movable ipsilateral 
axillary lymph nodes which are larger than 5 cm in greatest dimension are also staged as 
IIIA.10 There was 1 patient with Stage IIIB cancer, defined as an inflammatory tumor or any 
tumor invasive of the chest wall.10 There were 6 patients with Stage IIIC cancers, defined as 
any tumor metastatic to ipsilateral infraclavicular lymph nodes, ipsilateral supraclavicular 
lymph nodes, or both internal mammary and axillary nodes.10 Of these 13 Stage III patients, 
all received surgery: there were 9 mastectomies and 4 lumpectomies [Figure 1]. All of the 
patients received chemotherapy in either the neoadjuvant or adjuvant setting, or both 
[Figure 1]. 12 of the 13 patients were offered radiation therapy, and one patient was not 
recommended to receive radiation therapy due to the extent of her disease [Figure 1]. The 
patients attended regular follow up appointments. All treatments offered by LVHN for 
these patients was in accordance with the NCCN guidelines for treatment of Stage III locally 
advanced breast cancer, which recommends neoadjuvant chemotherapy: if responsive, it 
recommends lumpectomy or mastectomy followed by radiation to the chest wall and 
infraclavicular and supraclavicular lymph nodes.10 If the cancer does not respond to the 
first line of chemotherapy, additional systemic therapy and preoperative radiation are 
recommended.10 In addition, patients are recommended to attend follow up appointments 
regularly and receive yearly mammograms.10  
 There were 3 patients diagnosed with Stage IV TNBC [Table 1]. Stage IV, or 
metastatic cancer, is characterized by detectable metastases histologically proven larger 
than 0.2 mm in distant organs.10 Metastatic breast cancer is not curable, but it can be 
treated. All three patients received palliative chemotherapy: 2 of the patients received 
three or more chemotherapy regimens [Figure 1]. One patient received mastectomy, and 
one patient received palliative radiation therapy [Figure 1]. These treatments are in 
accordance with the NCCN guidelines for treatment of Stage IV TNBC which recommend 
three sequential lines of chemotherapy, with or further chemotherapy if the disease 
responds or transition to palliative care.10 
 The second goal of our study is to determine the frequency of BRCA mutations 
among TNBC patients seen at LVHN in 2013-14. All 62 patients were eligible to receive 
genetic testing as a result of their triple-negative diagnosis: of these 62 referrals, 25 
followed up with the genetic counselor and underwent genetic testing.9 4 patients tested 
positive for a mutation to the BRCA1 gene. None of the patients in our study tested positive 
for a BRCA2 mutation. These results indicate that 16% of TNBC patients seen by LVHN in 
2013-14 who received genetic testing carried a mutant BRCA gene. This result is consistent 
with the literature findings which suggest 15-20% of patients diagnosed with TNBC have a 
mutation in BRCA1.2 Furthermore, the average age of TNBC patients diagnosed at LVHN in 
2013-14 was determined as 61 years, while the average age at diagnosis for TNBC patients 
with BRCA mutation was significantly younger at 47 years. This result is also consistent 
with the literature suggesting that BRCA mutation is correlated with a younger age at TNBC 
diagnosis.3 
Conclusions 
 The goals of our study were to determine if the treatments offered to TNBC patients 
treated at LVHN in 2013-14 were in accordance with the NCCN Guidelines Version 2.2015 
and to determine the frequency of BRCA mutation among the population of those patients 
who had received genetic testing. We have shown the treatments offered to TNBC patients 
in 2013-14 were in accordance with the national guidelines. We have also determined the 
incidence of BRCA1 mutation to be 16% in a population of 25 TNBC patients who received 
genetic testing. Our results show the average age of BRCA mutant TNBC patients (47) to be 
significantly younger than the average age of all TNBC patients in our study (61). However, 
we report that of the 62 patients in our study, only 25 received genetic testing (~40%). A 
further subject of interest may be methods to mainstream these genetic tests. We hope that 
BRCA screening will gain more popularity in the future as a prognostic factor. 
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